Clinicopathological features of hepatoid adenocarcinoma of the stomach: A multicenter retrospective study

Area of Science:

• Gastroenterology
• Surgical Oncology
• Pathology

Background:

• Hepatoid adenocarcinoma of the stomach (HAS) is a rare, aggressive gastric cancer subtype (<1%).
• HAS is associated with frequent liver metastasis and poorer prognosis than conventional gastric cancer.
• Current treatment guidelines for HAS are lacking.

Purpose of the Study:

• To retrospectively analyze outcomes of HAS treated with gastrectomy and hepatectomy for liver metastasis.
• To identify prognostic factors for HAS.
• To suggest optimal treatment strategies for HAS, including chemotherapy and hepatectomy criteria.

Main Methods:

• Clinicopathological study of 19 HAS patients (2016-2018).
• Analysis included gastrectomy, hepatectomy for liver metastasis, and postoperative chemotherapy.
• Survival rates and recurrence after treatment were assessed.

Main Results:

• 19 male patients (mean age 70.9) diagnosed with HAS.
• 5-year survival rate of 67.7% after gastrectomy.
• Among 7 patients with liver metastasis, 5 underwent hepatectomy with a 3-year survival rate of 100% post-hepatectomy.

Conclusions:

• Prognosis for HAS may be better than previously reported (contrary to ~30% 3-year survival).
• Gastrectomy combined with hepatectomy for liver metastasis appears effective.
• Further insights into HAS management and treatment strategies are provided.